Medical

Acorda Therapeutics has presented data from a PK study of its diazepam nasal spray showing that dosing during seizure produces comparable pharmacokinetics to dosing immediately following a seizure. The company recently submitted an NDA for intranasal diazepam for the treatment of epilepsy and has said that it expects to market the product as early as 2014 if it is … [Read more...] about Study shows diazepam nasal spray administered during seizure comparable to dosing after seizure

Marinomed Biotechnologie has announced that a randomized, double-blind placebo-controlled study of more than 200 patients suffering from the common cold found that patients who received a Carragelose-based nasal spray reduced the duration of symptoms by 2.1 days. Data also showed that patients' viral load was significantly reduced. The study was published in … [Read more...] about Study shows nasal spray reduces duration of common cold symptoms

GlaxoSmithKline and Theravance have announced that a 12-week double-blind, parallel group Phase 3 study of their fluticasone furoate (FF)/vilanterol (VI) DPI (Breo/Relvar Ellipta) in almost 1,000 patients with moderate to severe asthma met its primary endpoint. According to the companies, both the 100/25mcg FF/VI and 200/25mcg FF/VI showed statistically significant … [Read more...] about Positive results for Phase 3 study of FF/VI for asthma

A study by the Cochrane Acute Respiratory Infections Group examined data from four studies involving almost 2,000 patients with acute sinusitis and determined that the benefits of intranasal corticosteroids (INCS) are "modest but clinically important." According to the authors, the evidence is limited but "supports the use of INCS as a monotherapy or as an adjuvant … [Read more...] about Study finds modest benefit of intranasal corticosteroids for acute sinusitis

According to Lightlake Therapeutics, initial results from a two-week PK study of intranasal naloxone for the treatment of opioid overdose shows that the nasal spray gets naloxone into the bloodstream as fast as injection. The study, which began September 23, 2013, was conducted in conjunction with the National Institute on Drug Abuse (NIDA). Lightlake CFO Kevin … [Read more...] about Positive results for Lightlake intranasal naloxone study

A study by Danish researchers published online November 25, 2013 by the Annals of Emergency Medicine found that intranasal fentanyl administered by ambulance workers prior to delivery of patients to the hospital appeared to be safe and effective. The study involved over 900 patients, including adults and children older than 8, who were in severe pain. The patients … [Read more...] about Study finds out-of-hospital intranasal fentanyl safe and effective

Cornerstone Therapeutics has launched Bethkis tobramycin inhalation solution for the treatment of cystic fibrosis patients with P. aeruginosa infections in the US, the company said. According to Cornerstone, one dose of Bethkis contains 300 mg of tobramycin in 4 mls of solution and can be delivered in about 15 minutes using a PARI LC Plus nebulizer. The company … [Read more...] about Cornerstone launches Bethkis tobramycin inhalation solution

Canadian cardiovascular drug development company Milestone Pharmaceuticals has initiated a Phase 1 clinical trial of its lead product, MSP-2017 intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT), the company announced. The randomized, double-blind, placebo-controlled crossover study will take place in … [Read more...] about Milestone initiates Phase 1 trial of intranasal calcium channel antagonist

Florida-based Puget Technologies has announced that its subsidiary Cannabis Biotech has initiated a research project to develop an intranasal formulation of cannabinoids, saying that the "project is targeted towards those who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it." The company said that the project will be … [Read more...] about Puget Technologies says it will develop intranasal cannabinoids